2015年版《中华人民共和国药典·临床用药须知》中含黄连及其炮制品成方制剂收载情况分析
|
摘要
目的:为规范含黄连及其炮制品成方制剂的合理应用提供参考。方法:查阅2015年版《中华人民共和国药典·临床用药须知》(中药成方制剂卷)一书,对其中含黄连及其炮制品成方制剂的收载情况进行汇总、分析。结果与结论:2015年版《中华人民共和国药典·临床用药须知》(中药成方制剂卷)中共收载含黄连及其炮制品的成方制剂127种,其中内科、外科、妇科、儿科、皮肤科、眼科、咽喉科、口腔科、骨伤科制剂分别有83、5、2、8、4、11、6、5、3种;含黄连片的成方制剂有120种(占94.49%),含酒黄连、姜黄连、萸黄连的成方制剂分别有2、4、1种;以黄连为君、臣、佐药的成方制剂分别有39、59、29种,以清热燥湿、泻火解毒的功效为主(104种,占81.89%)。主要品种包括麝香牛黄丸、葛根岑连片、开胃健脾丸等。通过对比黄连及其炮制品的功效,发现该书收载的相关品种存在炮制品名称不规范、黄连及其炮制品标示不统一和应用不规范等现象,相关内容仍有待进一步完善。临床应加强黄连药效基础及炮制标准的相关研究,并开展相关出版物的勘察纠错工作,以有助于提高含黄连及其炮制品成方制剂的合理用药水平。
OBJECTIVE:To provide reference for standardizing rational use of set prescription preparation containing Coptis chinensis and its processed product. METHODS:By retrieving 2015 edition of Chinese Pharmacopeia·Guidelines for Clinical Drug Use(volume of TCM set prescription),the inclusion of set prescription preparation containing C. chinensis and its processed product were summarized and analyzed. RESULTS&CONCLUSIONS:There were 127 set prescription preparations containing C.chinensis and its processed product included in 2015 edition of Chinese Pharmacopeia·Guidelines for Clinical Drug Use(volume of TCM set prescription),among which,there were 83,5,2,8,4,11,6,5 and 3 set prescription preparations for internal medicine, surgery, gynecology, pediatrics, dermatology, ophthalmology, pharyngology, stomatology, orthopedics and traumatology,respectively. There were 120 set prescription preparations containing C. chinensis(94.49%),2,4 and 1 set prescription preparations containing prepared C. chinensis with vino,prepared C. chinensis with ginger and prepared C. chinensis with Euodia rutaecarpa,respectively. There were 39,59 and 29 kinds of set prescription preparations with C. chinensis as main symptoms medicine,assists medicine and complication medicine,which were mainly for clearing heat,drying dampness,purging fire and detoxifying(104 kinds,81.89%). Main types included Shexiang niuhuang pills,Gegen cenlian tablets,Kaiwei jianpi pills,etc. By comparing the efficacy of C. chinensis and its processed product,it was found that the names of processed products were not standardized, the labeling of C. chinensis and its processed products were not uniform and the application was not standardized; the related contents still needed to be further improved. It is necessary to strengthen the research on the pharmacodynamic basis and processing standard of C. chinensis and carry out the investigation and correction of relevant publications in order to help improve the rational drug use level of set prescription preparations containing C. chinensis and its processed products.
OBJECTIVE:To provide reference for standardizing rational use of set prescription preparation containing Coptis chinensis and its processed product. METHODS:By retrieving 2015 edition of Chinese Pharmacopeia·Guidelines for Clinical Drug Use(volume of TCM set prescription),the inclusion of set prescription preparation containing C. chinensis and its processed product were summarized and analyzed. RESULTS&CONCLUSIONS:There were 127 set prescription preparations containing C.chinensis and its processed product included in 2015 edition of Chinese Pharmacopeia·Guidelines for Clinical Drug Use(volume of TCM set prescription),among which,there were 83,5,2,8,4,11,6,5 and 3 set prescription preparations for internal medicine, surgery, gynecology, pediatrics, dermatology, ophthalmology, pharyngology, stomatology, orthopedics and traumatology,respectively. There were 120 set prescription preparations containing C. chinensis(94.49%),2,4 and 1 set prescription preparations containing prepared C. chinensis with vino,prepared C. chinensis with ginger and prepared C. chinensis with Euodia rutaecarpa,respectively. There were 39,59 and 29 kinds of set prescription preparations with C. chinensis as main symptoms medicine,assists medicine and complication medicine,which were mainly for clearing heat,drying dampness,purging fire and detoxifying(104 kinds,81.89%). Main types included Shexiang niuhuang pills,Gegen cenlian tablets,Kaiwei jianpi pills,etc. By comparing the efficacy of C. chinensis and its processed product,it was found that the names of processed products were not standardized, the labeling of C. chinensis and its processed products were not uniform and the application was not standardized; the related contents still needed to be further improved. It is necessary to strengthen the research on the pharmacodynamic basis and processing standard of C. chinensis and carry out the investigation and correction of relevant publications in order to help improve the rational drug use level of set prescription preparations containing C. chinensis and its processed products.
引文
[1]季晓杭.左金丸古今文献研究及临床应用探讨[D].南京:南京中医药大学:2017.
[2]国家药典委员会.中华人民共和国药典:一部[S].2015年版.北京:中国医药科技出版社,2015:303-305.
[3]王影,刘文娟,崔瑛.黄连现代研究进展[J].中医学报,2014,29(11):1642-1645.
[4]邓晓威,谢宁.黄连素及其衍生物的药效学研究进展[J].中医药学报,2017,45(4):108-111.
[5]胡明姝.黄连不同炮制品的临床应用[J].中国处方药,2018,16(2):21-22.
[6]吴朝阳.黄连的不同炮制方法及临床药用经验[J].北方药学,2013,10(6):58.
[7]范景辉,赵玉梅,李志平.小檗碱的药理作用研究[J].中国药物经济学,2014,9(6):220-221.
[8]王凌,王少明,庄捷,等.不同炮制方法对黄连主成分含量及肠吸收的影响[J].中国临床药理学与治疗学,2011,16(2):165-169.
[9]降雪,贾天柱.黄连及其炮制品表观油水分布系数的测定[C]//武汉:中华中医药学会中药炮制分会2009年学术研讨会论文集,2009:427-429.
[10]王婷婷,钟凌云.姜制黄连炮制近年来研究进展[J].时珍国医国药,2016,27(2):427-429.
[11]杨伟鹏,王怡薇,王彦礼,等.吴茱萸汁炮制对黄连抗炎药效和苦寒药性的影响[J].中国中医药信息杂志,2013,20(8):42-44、47.
[12]蒋俊,徐江,贾晓斌,等.萸黄连饮片“反制”前后物质基础差异性研究[J].药物分析杂志,2011,31(1):43-50.
[13]刘琨,刘蜀宝.关于《中国药典》及《临床用药须知》不妥之处的讨论[J].中国药事,2009,23(8):786-787、789.
[14]杨俊.探讨中药不同炮制方法对中药药效的影响[J].中国实用医药,2014,9(25):238-239.
[15]陈虹.中药炮制规范化的药用探讨[J].中国现代药物应用,2012,6(7):112-113.
[16]蒋俊,贾晓斌,薛璟,等.黄连的炮制历史沿革及其炮制品现代研究进展[J].中国医院药学杂志,2010,30(2):156-158.
[17]钟凌云,孙莹莹,龚千锋.炮制影响黄连药性研究现状及展望[J].中草药,2010,41(2):323-325.
[18]陈博,万敬员.黄连现代中医临证研究[J].中华中医药学刊,2018,36(10):2505-2508.
[2]国家药典委员会.中华人民共和国药典:一部[S].2015年版.北京:中国医药科技出版社,2015:303-305.
[3]王影,刘文娟,崔瑛.黄连现代研究进展[J].中医学报,2014,29(11):1642-1645.
[4]邓晓威,谢宁.黄连素及其衍生物的药效学研究进展[J].中医药学报,2017,45(4):108-111.
[5]胡明姝.黄连不同炮制品的临床应用[J].中国处方药,2018,16(2):21-22.
[6]吴朝阳.黄连的不同炮制方法及临床药用经验[J].北方药学,2013,10(6):58.
[7]范景辉,赵玉梅,李志平.小檗碱的药理作用研究[J].中国药物经济学,2014,9(6):220-221.
[8]王凌,王少明,庄捷,等.不同炮制方法对黄连主成分含量及肠吸收的影响[J].中国临床药理学与治疗学,2011,16(2):165-169.
[9]降雪,贾天柱.黄连及其炮制品表观油水分布系数的测定[C]//武汉:中华中医药学会中药炮制分会2009年学术研讨会论文集,2009:427-429.
[10]王婷婷,钟凌云.姜制黄连炮制近年来研究进展[J].时珍国医国药,2016,27(2):427-429.
[11]杨伟鹏,王怡薇,王彦礼,等.吴茱萸汁炮制对黄连抗炎药效和苦寒药性的影响[J].中国中医药信息杂志,2013,20(8):42-44、47.
[12]蒋俊,徐江,贾晓斌,等.萸黄连饮片“反制”前后物质基础差异性研究[J].药物分析杂志,2011,31(1):43-50.
[13]刘琨,刘蜀宝.关于《中国药典》及《临床用药须知》不妥之处的讨论[J].中国药事,2009,23(8):786-787、789.
[14]杨俊.探讨中药不同炮制方法对中药药效的影响[J].中国实用医药,2014,9(25):238-239.
[15]陈虹.中药炮制规范化的药用探讨[J].中国现代药物应用,2012,6(7):112-113.
[16]蒋俊,贾晓斌,薛璟,等.黄连的炮制历史沿革及其炮制品现代研究进展[J].中国医院药学杂志,2010,30(2):156-158.
[17]钟凌云,孙莹莹,龚千锋.炮制影响黄连药性研究现状及展望[J].中草药,2010,41(2):323-325.
[18]陈博,万敬员.黄连现代中医临证研究[J].中华中医药学刊,2018,36(10):2505-2508.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |